This paper was based on the postoperative chemotherapy of glioma. Glioma is the most common malignant invasive-growing tumor in the skull, with high mortality, high recurrence rate and low cure rate. Surgery and chemotherapy are often combined in clinical treatment. The first-line chemotherapy drug for brain glioma is timorazolamide which can cross the blood-brain barrier. Although the postoperative efficacy with timorazolamide is higher than radiotherapy, the five-year survival rate was only 9.8%. Other effective anti-tumor drugs such as paclitaxel, which can’t penetrate the blood-brain barrier, fail to be applied in clinical trials. In order to keep drugs efficiently concentrated in postoperative residual tumor, Professor Zhang’s group developed the autologous neutrophils as vectors which carry antitumor drug paclitaxel-loaded liposomes. After injected intravenously to the postoperative orthotopic glioma in mice model, the neutrophils crossed the blood-brain barrier through deformation under the tropism to inflammatory factors, thus implemented the effective independent targeted drug delivery, restraining the orthotopic glioma postoperative recurrence and development in mice.
The research based on specific diseases and their pathological factors, broke the limitation of the traditional receptor-ligand binding design. The result set up new technology platform for drugs crossing the blood-brain barrier and brain diseases treatment. It was expected to be applied for the treatment of inflammation and related diseases.
It took us 5 years and 3 months to overcome all difficulties and persist in exploring the idea. The paper was funded by China National Natural Science Foundation and the Open Project Program of State Key Laboratory of Natural Medicines, China Pharmaceutical University. The paper was also supported by Jiangsu Key Laboratory of Drug Discovery in Metabolic Disease.
The first author of the paper is Xue Jingwei, the 2014th Ph.D majored in chemical medicine. The corresponding author is Prof. Zhang Can, and the co-corresponding author is Prof. Mo Ran. The second and other main authors are followed by: Zhao Zekai,2017th Ph.D in pharmacy, 2015th Master Zhang Lei in pharmacy, Dr. Xue Lingjing, 2016th Master Shen Siyang and Wei Zhuoyuan in pharmacy, 2017th Master Wen Yajing in pharmacy, 2013th Master Wang Lu in chemical medicine,etc. Many “unsigned authors” in our group, including Su Zhigui, Ju CaoYun, Wang Cong, Zhang Yong, Hou Siyuan, Tang Chunming, Kang Zisheng, Zhang Yidi, Dai Lili, Zhang Yan, Zhou Anwei and Xie Daping, contributed a lot for many supplementary experiments.
Address: New Research Building 1801-1803, New Drug Research Center, Institute of Pharmaceutical Science, Xuanwu Campus, #24 Tong Jia Xiang, Nanjing, Jiangsu Province Zip code: 210009 Tel: 025-83271171 (Lab / Fax) E-mail:firstname.lastname@example.org Website: http://enzcgroup.cpu.edu.cn/